These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8999204)

  • 1. The real world calls. Evolving operationalization of standards by users.
    Med Care; 1996 Dec; 34(12 Suppl):DS173-5. PubMed ID: 8999204
    [No Abstract]   [Full Text] [Related]  

  • 2. Current efforts in standards development. United States.
    Power EJ
    Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327
    [No Abstract]   [Full Text] [Related]  

  • 3. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation.
    Mullahy J
    Med Care; 1996 Dec; 34(12 Suppl):DS124-35. PubMed ID: 8969321
    [No Abstract]   [Full Text] [Related]  

  • 4. Towards a reference case for economic evaluation of osteoporosis treatments.
    Coyle D; Tosteson AN
    J Rheumatol Suppl; 2003 Dec; 68():31-6. PubMed ID: 14712620
    [No Abstract]   [Full Text] [Related]  

  • 5. Towards a reference case for use in future economic evaluations of interventions in osteoarthritis.
    Drummond M; Maetzel A; Gabriel S; March L
    J Rheumatol Suppl; 2003 Dec; 68():26-30. PubMed ID: 14712619
    [No Abstract]   [Full Text] [Related]  

  • 6. Adapting pharmacoeconomic data and methods to extend the postpublication utility of analyses.
    Lyles A
    Clin Ther; 2009 Jan; 31(1):192-3. PubMed ID: 19243717
    [No Abstract]   [Full Text] [Related]  

  • 7. [Economic evaluation of drugs. Effectiveness in diabetes therapy].
    Schöffski O
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S106-9; discussion S124-6. PubMed ID: 18686218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Industry responsibility in interactive computer modeling.
    Mauskopf J
    Med Care; 1996 Dec; 34(12 Suppl):DS165-72. PubMed ID: 8969323
    [No Abstract]   [Full Text] [Related]  

  • 9. Modeling for health care and other policy decisions: uses, roles, and validity.
    Johnson FR; Paul JE
    Value Health; 2002; 5(1):62-3; author reply 61-2. PubMed ID: 11873387
    [No Abstract]   [Full Text] [Related]  

  • 10. Defining types of economic evaluation.
    Ngorsuraches S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S21-7. PubMed ID: 19255985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of health economic information by reimbursement authorities.
    Drummond MF
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economics--what the nephrologist should know.
    Palmer AJ
    Nephrol Dial Transplant; 2005 Jun; 20(6):1038-41. PubMed ID: 15840678
    [No Abstract]   [Full Text] [Related]  

  • 13. [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations].
    Postma MJ; Kwik JJ; Rutten WJ; de Jong-van den Berg LT; Brouwers JR
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1082-7. PubMed ID: 12085558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Ann Pharmacother; 2006 Mar; 40(3):524-8. PubMed ID: 16507612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced purchase commitments for a malaria vaccine.
    Natl Bur Econ Res Bull Aging Health; 2005; (12):1-2. PubMed ID: 16175672
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacoeconomics: determining the value of drug therapy.
    Peterson C
    Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The convergence of psoriasis treatment cost-effectiveness over time: "real world" considerations in economic modeling.
    Goldberg LD
    J Am Acad Dermatol; 2008 Jun; 58(6):1073-5. PubMed ID: 18485990
    [No Abstract]   [Full Text] [Related]  

  • 19. Accumulating evidence for the case of differential discounting.
    Postma MJ; Parouty M; Westra TA
    Expert Rev Clin Pharmacol; 2013 Jan; 6(1):1-3. PubMed ID: 23272787
    [No Abstract]   [Full Text] [Related]  

  • 20. Transparency of economic evaluations of health technologies.
    Rovira J
    Pharmacoeconomics; 2008; 26(3):181-3. PubMed ID: 18282013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.